Building a Biotech Catalyst Calendar That Actually Works

Why a Catalyst Calendar Is Your Core Tool

Biotech returns are driven by catalysts — scheduled events that resolve uncertainty and reprice stocks. A catalyst calendar is simply a structured, forward-looking list of those events across the companies you follow. Done well, it turns biotech's chaos into a navigable schedule and is arguably the single most useful tool a biotech investor maintains.

The catch: a calendar is only as good as its accuracy and upkeep. A stale calendar is worse than none, because it creates false confidence about when things will happen.

Which Events to Track

A useful calendar covers the events that move stocks:

• PDUFA dates — FDA decision deadlines, the classic binary catalyst.
• Advisory committee meetings — often pre-PDUFA, with their own market impact.
• Phase 3 and Phase 2 readouts — pivotal and proof-of-concept data.
• FDA approval decisions and label expansions via supplemental applications.
• Earnings — where cash runway, burn, and guidance update.
• Regulatory milestones — filings, designations, and submission completions.

Not every event deserves equal weight. A pivotal readout for a company's lead asset is a different order of importance from a minor trial update. Tag events by materiality so your calendar surfaces what matters.

Where the Dates Come From

Reliable catalyst dates come from primary sources, not rumor:

1. Company disclosures — guidance in earnings calls, 8-K filings, and investor presentations.
2. ClinicalTrials.gov — the primary completion date is your best proxy for a trial readout. Watch for changes; a pushed date signals a delay.
3. FDA actions — PDUFA dates and advisory committee announcements.

The crucial discipline is to capture date confidence. "Second half of 2026" is not the same as a specific PDUFA date. A good calendar distinguishes firm dates from soft guidance, so you don't position with false precision.

The Maintenance Problem

Catalyst dates drift constantly: trials slip, PDUFA dates get extended, readouts move from "Q2" to "mid-year" to "second half." A calendar built once and never updated quickly becomes misinformation. Maintenance is the hard part, and it's where most manually built calendars fail:

• Trial completion dates change on ClinicalTrials.gov without fanfare.
• Companies revise guidance on earnings calls.
• The FDA extends or reschedules.

Keeping a multi-company calendar current by hand is genuinely difficult — which is exactly why automated, continuously updated catalyst tracking exists. A calendar that updates hourly from primary sources removes the staleness problem that undermines manual ones.

Using the Calendar

A calendar isn't just a list — it's a decision tool:

• Plan position sizing and timing around upcoming binary events (see our piece on binary events).
• Spot clustering — multiple catalysts for one company, or competing readouts in the same indication.
• Cross-reference with the balance sheet — a thin runway heading into a catalyst is a financing-risk flag.
• Avoid surprises — the worst outcome is being blindsided by an event you should have known was coming.

Applying It

Start by listing the material catalysts for every company you follow, sourced from disclosures and ClinicalTrials.gov, each tagged with its date confidence and importance. Then commit to keeping it current — or use a tool that does. Review the programs behind each event on their company pages and browse the consolidated biotech catalyst calendar to see how upcoming events stack up.

In a catalyst-driven sector, the investor with the most accurate forward calendar has a structural edge — and the one with a stale calendar has a liability.